Document Detail


Integrating leptin and cAMP signalling pathways in triple-negative breast cancer cells.
MedLine Citation:
PMID:  23276914     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Breast cancer is a major cause of cancer death in women in the world. Triple-negative breast cancers, which accounts for 10-20% of all mammary tumours, are characterised by an aggressive phenotype, are often found in younger women and have been associated with poor prognosis. Obesity increases the risk for triple-negative breast cancer occurrence. Because triple-negative breast cancer patients are unresponsive to current targeted therapies and other treatment options are only partially effective, new pharmacological approaches are warranted. The obesity-linked adipokine, leptin, is a well known mitogen/survival factor in breast cancer cells and several studies have addressed the role of leptin in breast cancer pathogenesis and progression. Surprisingly, recent in vitro studies have shown that leptin enhances the anti-proliferative effects of cAMP elevation in triple-negative breast cancer cells by apoptosis induction. In the current review, we discuss on the role of cAMP as a growth suppressor and of leptin as a growth promoting factor in breast cancer cells and we will focus on the molecular pathways involved in the antiproliferative interaction between leptin and cAMP elevation. The rationale for the possible development of a simple, cheap and innovative approach for therapeutic intervention in triple-negative breast cancer, based on the use of cAMP elevating drugs at lower and tolerable doses, will be also discussed.
Authors:
Annamaria Spina; Francesca Di Maiolo; Antonietta Esposito; Raffaella D'Auria; Davide Di Gesto; Emilio Chiosi; Luca Sorvillo; Silvio Naviglio
Related Documents :
24509074 - Computer-aided detection of breast cancer on mammograms: a swarm intelligence optimized...
24417674 - Women's reflections on fertility and motherhood after breast cancer and its treatment.
23617294 - Selective capsulotomies of the expanded breast as a remodelling method in two-stage bre...
24146864 - P16 and p53 play distinct roles in different subtypes of breast cancer.
15591034 - Correlation of mrna for oestrogen receptor beta splice variants erbeta1, erbeta2/erbeta...
10668064 - S. p. cotton, e. g. levine, c. m. fitzpatrick, k. h. dold and e. targ, 'exploring the r...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  133-44     Citation Subset:  IM    
Affiliation:
Department of Biochemistry and Biophysics, Second University of Naples, Medical School, Via L. De Crecchio 7, 80138 Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / drug therapy*,  physiopathology
Cell Line, Tumor
Cyclic AMP / agonists,  physiology*,  therapeutic use
Drug Resistance, Neoplasm / drug effects
Female
Humans
Leptin / physiology*,  therapeutic use
STAT3 Transcription Factor / metabolism
Signal Transduction / drug effects*
Chemical
Reg. No./Substance:
0/Leptin; 0/STAT3 Transcription Factor; 0/STAT3 protein, human; 60-92-4/Cyclic AMP

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nutrition in oncologic patients during antiblastic treatment.
Next Document:  Aromatic amines: use in azo dye chemistry.